iX Biopharma remains a “buy” for PhillipCapital analyst Tay Wee Kuang, with an unchanged target price of 44.5 cents, as the specialty pharmaceutical company announced that it has entered into a strategic cooperation agreement to expand its presence in China.

The agreement was signed with China Resources Pharmaceutical Commercial Group Co (CRPCG), a subsidiary of Hong Kong-listed China Resources Pharmaceutical Group on April 6.

Under the agreement, CRPCG and iX Biopharma will work together to commercialise iX Biopharma’s entire specialty pharmaceutical and nutraceutical portfolio in China.


To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook